WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009063171) NOVEL ROTIGOTINE SALTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/063171    International Application No.:    PCT/GB2008/003741
Publication Date: 22.05.2009 International Filing Date: 06.11.2008
IPC:
C07D 333/20 (2006.01), A61K 31/381 (2006.01), A61P 25/16 (2006.01)
Applicants: PLIVA HRVATSKA d.o.o. [HR/HR]; Ulica grada Vukovara 49, 10000 Zagreb (HR) (For All Designated States Except US).
AVDAGIC, Amir [HR/HR]; (HR) (For US Only).
MUNDORFER, Tina [HR/HR]; (HR) (For US Only).
MARKOVIC, Marina [HR/HR]; (HR) (For US Only).
SILJKOVIC, Zvonimir [HR/HR]; (HR) (For US Only).
BUCKS, Teresa, Anne [GB/GB]; (GB) (LR only)
Inventors: AVDAGIC, Amir; (HR).
MUNDORFER, Tina; (HR).
MARKOVIC, Marina; (HR).
SILJKOVIC, Zvonimir; (HR)
Agent: BUCKS, Teresa, Anne; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB)
Priority Data:
60/988,587 16.11.2007 US
Title (EN) NOVEL ROTIGOTINE SALTS
(FR) NOUVEAUX SELS DE ROTIGOTINE
Abstract: front page image
(EN)The present invention relates to new salts of N,N-disubstituted aminotetralins, such as rotigotine hydrobromide p-toluenesulfonate, heminaphthalene-l,5-disulfonate, tartrate, and phosphate. Also provided herein are methods of making the new salts and using them for the treatment of diseases that may be prevented, ameliorated or eliminated by the administration of a dopamine D2 receptor agonist or an antiparkinsonian agent.
(FR)La présente invention concerne de nouveaux sels d'aminotétralines N,N-disubstituées, tels que le bromhydrate de rotigotine p-toluènesulfonate, l'héminaphtalène-1,5-disulfonate, le tartrate, et le phosphate. La présente invention concerne également des procédés de fabrication des nouveaux sels et d'utilisation de ceux-ci pour le traitement de maladies qui peuvent être empêchées, améliorées ou éliminées par l'administration d'un agoniste des récepteurs D2 de la dopamine ou d'un agent antiparkinsonien.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)